Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for ESS40013

Result Summary for ESS40013

Result Summary

Protocol ID:	ESS40013
Clinical Study ID:	ESS40013
Official Title:	A Phase IV Multi-center Study of the Efficacy and Safety of 48-Week Induction Treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet BID) + Efavirenz (600mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment with TRIZIVIR…
Phase:	Phase 4
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	trizivir;trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Markowitz M, Hill-Zabala C, Lang J, et al. Maintenance with Trizivir or Trizivir + efavirenz for 48 weeks following a 48-week induction with Trizivir + efavirenz in antiretroviral-naïve HIV-1 infected subjects (ESS40013). XV International AIDS Conference, Bangkok, Thailand, July 11-16, 2004. [presentation LbOrB14] Markowitz M, Lang J, DeJesus E, et al. Induction of antiretroviral-naïve HIV-infected subjects with Trizivir and Sustiva for 48 weeks (ESS40013). 2nd IAS Conference on Pathogenesis and Treatment, Paris, France, July 13-16, 2003. [presentation 42]